AASLD2014替诺福韦：安全有效预防乙肝病毒的母亲对婴儿的传:

StephenW

1851
Tenofovir Disoproxil: Effective and Safe in Prevention of Mother-to-child Transmission of Hepatitis B Virus
Hongfei Huang, Quanxin Wu, Yuming Wang;
Department of Infectious Diseases, Southwest Hospital Third Military Medical University, Chongqing, China

Background Mother-to-child transmission (MTCT) of hepatitis B virus(HBV) still remains a world concerned question. Previous studies have demonstrated the effectiveness of telbivudine (LdT) and lamivudine (LAM) in pregnancy, but there were few data about tenofovir (TDF), also it is a controversal problem on the choice of antiviral drugs and the appropriate time to start therapy. Purpose To evaluate the safety and reliability of tenofovir in preventing mother-to-child transmission of HBV during pregnancy. Methods We totally enrolled 38 HBV infected pregnant women with HBsAg and HBeAg positive since 8/2009 until 5/2013. Among these patients, 21 women were treated with TDF (300mg/d) alone; 11 were treated with TDF (300mg/d) +LDT (600mg/d), while 6 were treated with TDF (300mg/d) +LAM (100mg/d) during pregnancy. All the babies were injected with hepatitis B vaccine and immunoglobulin according to the standard protocal after birth. Mothers co-infected with other liver diseases were excluded from the study. Results In our study, 13 mothers started treatment at the first trimester (0-11 weeks); and 4 began treatment at the second trimester (15-24 weeks); while 21 started treatment at the third trimester (28-39 weeks). Five mothers were with ALT elevation before treatment which ranged from 1.8×ULN to 12.2×ULN and 2 of them decreased to normal level at delivery. All the infants cordblood were detected negative for HBV DNA and born with no congenital diseases. All babies were detected negative for HBsAg and HBV DNA at 20-48 weeks . Conclusion It is safe and effective by using tenofovir in prevent mother-to-child transmission of HBV during the whole pregnancy.

Disclosures:

The following people have nothing to disclose: Hongfei Huang, Quanxin Wu, Yuming Wang

StephenW

1851
替诺福韦：安全有效预防乙肝病毒的母亲对婴儿的传染
鸿飞黄，全兴吴玉明王;
传染病西南医院第三军医大学，重庆，中国

乙型肝炎病毒（HBV）的背景母亲向婴儿传播（母婴传播）仍然是一个全球关注的问题。以往的研究已经证明替比夫定（LDT）和拉米夫定（LAM）在怀孕的成效，但也有关于替诺福韦（TDF）的数据很少，也实在是对抗病毒药物的选择和适当的时候开始治疗的controversal问题。目的评价替诺福韦的安全性和可靠性，防止怀孕期间母亲向婴儿传播乙肝病毒的。方法：我们完全纳入38乙肝感染孕妇HBsAg和HBeAg阳性，因为8/2009直到二千○十三分之五。在这些患者中，21名妇女与TDF（300毫克/天）单独处理; 11人与TDF（300毫克/天）+ LDT（600毫克/天）治疗，而6例与TDF（300毫克/天）+林（100毫克/天），在怀孕期间治疗。所有的宝宝都根据出生后的标准protocal注射了乙肝疫苗和免疫球蛋白。母亲共感染与其它肝脏疾病被排除在研究之外。结果在我们的研究中，13个准妈妈开始治疗的前三个月（0-11周）; 4开始处理在孕中期（15-24周）;而21开始处理在孕晚期（28-39周）。五是母亲与治疗前ALT升高从1.8×ULN范围为12.2×ULN，其中2下降至正常水平发货。所有cordblood的婴儿被检测为阴性的HBV DNA和出生时没有先天疾病。所有的婴儿进行检测乙肝表面抗原阴性和HBV DNA在20-48周。结论是安全和有效的利用，整个怀孕期间的替诺福韦在防止母亲传染给孩子乙肝病毒。

披露：

下面的人都没有透露：鸿飞黄，泉鑫武，王钰明

重韧

我看看到一个报告是替比夫定。好像用的人生下的小孩全是阴性的。

齐欢畅2

马克

咬牙硬挺

感谢分享

lain88

表示服用两年多，两个宝宝都很健康

齐欢畅2